Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpSCF in Moderate to Severe Atopic Dermatitis
NCT06101823Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of OpSCF in atopic dermatitis (AD), sponsored by Insmed Incorporated. Started Nov 2023; status: completed.
02
Drugs
OpSCF
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06101823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101823.